

> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 07:28:04 ON 15 JUL 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jul 2009 VOL 151 ISS 3
 FILE LAST UPDATED: 14 Jul 2009 (20090714/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.


CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases will soon be updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

=> d stat que 18
 L1 STR




NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE
 L3 107 SEA FILE=REGISTRY SSS FUL L1
 L4 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE
 L5 14 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
 L6 26 SEA FILE=HCAPLUS ABB=ON PLU=ON L5
 L7 20506 SEA FILE=HCAPLUS ABB=ON PLU=ON ("SMALL-CELL LUNG CARCINOMA"/C
 V OR "CARCINOMA (L) PULMONARY SMALL-CELL"/CV OR "LUNG (L)
 SMALL-CELL CARCINOMA"/CV OR "LUNG, NEOPLASM (L) SMALL-CELL
 CARCINOMA"/CV OR "LUNG OAT CELL CARCINOMA"/CV OR "LUNG SMALL
 CELL CANCER"/CV) OR ("SMALL CELL CARCINOMA"/CV OR "SMALL CELL
 LUNG CANCER"/CV OR "SMALL LUNG CELL CARCINOMA"/CV OR "SMALL-CEL
 L CARCINOMA (LUNG)"/CV OR "SMALL-CELL CARCINOMA (PULMONARY)"/CV
) OR SMALL(L)CELL(L)LUNG(L) (CANCER? OR CARCINOMA)
 L8 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 AND L7

=> d ibib abs hitstr l8 1-4

L8 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009:583215 HCAPLUS Full-text
 DOCUMENT NUMBER: 150:506980
 TITLE: Combination of anti-angiogenic substance and
 anti-tumor platinum complex
 INVENTOR(S): Yamamoto, Yuji
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 97pp.

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009060945	A1	20090514	WO 2008-JP70321	20081107
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2007-986641P P 20071109

OTHER SOURCE(S): MARPAT 150:506980

AB The object is to discover a pharmaceutical composition having an excellent anti-tumor effect and a therapeutic method for cancer. 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, an analogous compound or a pharmacol. acceptable salt thereof, or a solvate of the compound, the analogous compound or the pharmacol. acceptable salt can exhibit an excellent anti-tumor effect when used in combination with an anti-tumor platinum complex.


IT 417716-92-8, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 417716-92-8D, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, salts 417719-50-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(combination of antiangiogenic substance and antitumor platinum complex for combination chemotherapy)

RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417716-92-8 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy]-7-methoxy- (CA INDEX NAME)



RN 417719-50-7 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(1R,2S)-2-fluorocyclopropyl] amino] carbonyl] amino] phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1065363 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 150:297980
 TITLE: Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
 AUTHOR(S): Matsui, Junji; Funahashi, Yasuhiro; Uenaka, Toshimitsu; Watanabe, Tatsuo; Tsuruoka, Akihiko; Asada, Makoto
 CORPORATE SOURCE: Discovery Research Laboratories II, Eisai Co. Ltd., Tokodai, Tsukuba, Japan

SOURCE: Clinical Cancer Research (2008), 14(17), 5459-5465
 CODEN: CCREF4; ISSN: 1078-0432
 PUBLISHER: American Association for Cancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB PURPOSE: Vascular endothelial growth factor (VEGF)-C/VEGF-receptor 3 (VEGF-R3) signal plays a significant role in lymphangiogenesis and tumor metastasis based on its effects on lymphatic vessels. However, little is known about the effect of inhibiting VEGF-R3 on lymphangiogenesis and lymph node metastases using a small-mol. kinase inhibitor. Exptl. Design: We evaluated the effect of E7080, a potent inhibitor of both VEGF-R2 and VEGF-R3 kinase, and bevacizumab on lymphangiogenesis and angiogenesis in a mammary fat pad xenograft model of human breast cancer using MDA-MB-231 cells that express excessive amts. of VEGF-C. Lymphangiogenesis was determined by lymphatic vessel d. (LVD) and angiogenesis by microvessel d. (MVD). RESULTS: In contrast to MDA-MB-435 cells, which expressed a similar amount of VEGF to MDA-MB-231 cells with an undetectable amount of VEGF-C, only MDA-MB-231 exhibited lymphangiogenesis in the primary tumor. E7080 but not bevacizumab significantly decreased LVD within the MDA-MB-231 tumor. E7080 and bevacizumab decreased MVD in both the MDA-MB-231 and MDA-MB-435 models. E7080 significantly suppressed regional lymph nodes and distant lung metastases of MDA-MB-231, whereas bevacizumab significantly inhibited only lung metastases. E7080 also decreased both MVD and LVD within the metastatic nodules at lymph nodes after resection of the primary tumor. CONCLUSIONS: Inhibition of VEGF-R3 kinase with E7080 effectively decreased LVD within MDA-MB-231 tumors, which express VEGF-C. Simultaneous inhibition of both VEGF-R2 and VEGF-R3 kinases by E7080 may be a promising new strategy to control regional lymph node and distant lung metastases.


IT 417716-92-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(E 7080; dual tyrosine kinase inhibitor of VEGF-R2 and VEGF-R3, E7080 decreased lymphangiogenesis, angiogenesis, lymph node and lung metastasis in human breast cancer cell xenografted into mouse)

RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:14364 HCAPLUS Full-text

DOCUMENT NUMBER: 148:253561

TITLE: E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

AUTHOR(S): Matsui, Junji; Yamamoto, Yuji; Funahashi, Yasuhiro; Tsuruoka, Akihiko; Watanabe, Tatsuo; Wakabayashi, Toshiaki; Uenaka, Toshimitsu; Asada, Makoto

CORPORATE SOURCE: Tsukuba Research Laboratories, Tsukuba, Ibaraki, 300-2635, Japan

SOURCE: International Journal of Cancer (2007), Volume Date 2008, 122(3), 664-671

CODEN: IJCNW; ISSN: 0020-7136

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB E7080 is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. In this study, we show the inhibitory activity of E7080 against SCF-induced angiogenesis in vitro and tumor growth of SCF-producing human small cell lung carcinoma H146 cells in vivo. E7080 inhibits SCF-driven tube formation of HUVEC, which express SCF receptor, KIT at the IC50 value of 5.2 nM and it was almost identical for VEGF-driven one (IC50 = 5.1 nM). To assess the role of SCF/KIT signaling in tumor angiogenesis, we evaluated the effect of imatinib, a selective KIT kinase inhibitor, on tumor growth of H146 cells in nude mice. Imatinib did not show the potent antitumor activity in vitro (IC50 = 2,200 nM), because H146 cells did not express KIT. However, oral administration of imatinib at 160 mg/kg clearly slowed tumor growth of H146 cells in nude mice, accompanied by decreased microvessel d. Oral administration of E7080 inhibited tumor growth of H146 cells at doses of 30 and 100 mg/kg in a dose-dependent manner and caused tumor regression at 100 mg/kg. While anti-VEGF antibody also slowed tumor growth, it did not cause tumor regression. These results indicate that KIT signaling has a role in tumor angiogenesis of SCF-producing H146 cells, and E7080 causes regression of H146 tumors as a result of antiangiogenic activity mediated by inhibition of both KIT and VEGF receptor signaling. E7080 may provide therapeutic benefits in the treatment of SCF-producing tumors.

IT 417716-92-8


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(E 7080; E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition)

RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-


[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:780539 HCAPLUS Full-text
 DOCUMENT NUMBER: 141:289013
 TITLE: c-Kit kinase inhibitor
 INVENTOR(S): Yamamoto, Yuji; Watanabe, Tatsuo; Okada, Masayuki;
 Tsuruoka, Akihiko
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080462	A1	20040923	WO 2004-JP3087	20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040253205	A1	20041216	US 2004-797903	20040310
EP 1604665	A1	20051214	EP 2004-719054	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.:			JP 2003-62823	A 20030310
			JP 2003-302803	A 20030827
			WO 2004-JP3087	W 20040310
OTHER SOURCE(S):			MARPAT 141:289013	
GI				




AB It is found out that a compound represented by the following general formula I (R1 = Me, etc.; R2 = cyano, etc.; R3 = H, etc.; and R4 = H, etc.) shows a potent c-Kit kinase inhibitory activity and suppresses the proliferation of cancer cells activated by c-Kit kinase both in vitro and in vivo. Thus, a novel anticancer agent showing a c-Kit kinase inhibitory activity is found out.

IT 417716-92-8, 4-(3-Chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (c-Kit kinase inhibitor)

RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d stat que l11

L1 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE

L3 107 SEA FILE=REGISTRY SSS FUL L1

L4 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE

L5 14 SEA FILE=REGISTRY SUB=L3 SSS FUL L4

L6 26 SEA FILE=HCAPLUS ABB=ON PLU=ON L5

L7 20506 SEA FILE=HCAPLUS ABB=ON PLU=ON ("SMALL-CELL LUNG CARCINOMA"/C
V OR "CARCINOMA (L) PULMONARY SMALL-CELL"/CV OR "LUNG (L)
SMALL-CELL CARCINOMA"/CV OR "LUNG, NEOPLASM (L) SMALL-CELL
CARCINOMA"/CV OR "LUNG OAT CELL CARCINOMA"/CV OR "LUNG SMALL
CELL CANCER"/CV) OR ("SMALL CELL CARCINOMA"/CV OR "SMALL CELL

LUNG CANCER"/CV OR "SMALL LUNG CELL CARCINOMA"/CV OR "SMALL-CELL
 L CARCINOMA (LUNG)"/CV OR "SMALL-CELL CARCINOMA (PULMONARY)"/CV
) OR SMALL(L)CELL(L)LUNG(L) (CANCER? OR CARCINOMA)
 L8 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 AND L7
 L9 22 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 NOT L8
 L10 18 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND (?CANCER? OR ?CARCIN?
 OR ?TUMOR? OR ?MALIG? OR ?NEOPLAS?)
 L11 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L10 AND (LUNG OR PULMON?)

=> d ibib abs hitstr l11 1-6

L11 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:863627 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:235192
 TITLE: Preparation of urea derivatives containing nitrogenous
 aromatic ring compounds as inhibitors of angiogenesis
 INVENTOR(S): Funahashi, Yasuhiro; Tsuruoka, Akihiko; Matsukura,
 Masayuki; Haneda, Toru; Fukuda, Yoshio; Kamata,
 Junichi; Takahashi, Keiko; Matsushima, Tomohiro;
 Miyazaki, Kazuki; Nomoto, Ken-Ichi; Watanabe, Tatsuo;
 Obaishi, Hiroshi; Yamaguchi, Atsumi; Suzuki, Sachi;
 Nakamura, Katsuji; Mimura, Fusayo; Yamamoto, Yuji;
 Matsui, Junji; Matsui, Kenji; Yoshiba, Takako; Suzuki,
 Yasuyuki; Arimoto, Itaru
 PATENT ASSIGNEE(S): Eisai Co., Ltd, Japan
 SOURCE: U.S., 458pp., Cont.-in-part of Appl. No.
 PCT/JP01/09221.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7253286	B2	20070807	US 2003-420466	20030418
US 20040053908	A1	20040318		
WO 2002032872	A1	20020425	WO 2001-JP9221	20011019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1506962	A2	20050216	EP 2004-25700	20011019
EP 1506962	A3	20050302		
EP 1506962	B1	20080702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, FI, CY, TR				
EP 1777218	A1	20070425	EP 2006-23078	20011019
EP 1777218	B1	20081231		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,				
NL, PT, SE, TR				
CN 101024627	A	20070829	CN 2007-10007096	20011019


CN 101029022	A	20070905	CN 2007-10007097	20011019
ES 2282299	T3	20071016	ES 2001-976786	20011019
ZA 2003003567	A	20040810	ZA 2003-3567	20030508
JP 2005272474	A	20051006	JP 2005-124034	20050421
US 20060247259	A1	20061102	US 2005-293785	20051202
US 20060160832	A1	20060720	US 2006-347749	20060203
AU 2006203099	A1	20060810	AU 2006-203099	20060719
AU 2006236039	A1	20061207	AU 2006-236039	20061116
AU 2006236039	B2	20080522		

PRIORITY APPLN. INFO.:

	JP 2000-320420	A	20001020
	JP 2000-386195	A	20001220
	JP 2001-46685	A	20010222
	WO 2001-JP9221	A2	20011019
	AU 2001-295986	A3	20011019
	AU 2001-95986	TO	20011019
	CN 2001-819710	A3	20011019
	EP 2001-976786	A3	20011019
	JP 2002-536056	A3	20011019
	US 2003-420466	A3	20030418
	US 2005-293785	A1	20051202

OTHER SOURCE(S): MARPAT 147:235192

GI



AB N-aryl or N-heteroarylurea derivs. represented by the general formula Ag-Xg-Yg-Tg1 or salts thereof, or hydrates of both [wherein Ag = (un)substituted C6-14 aryl or 5- to 14-membered heterocyclic group; Xg = single bond, O, S, C1-6 alkylene, SO, SO2, (un)substituted NH; Yg = (un)substituted C6-14 aryl, 5- to 14-membered heterocyclic group, C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl-C1-6 alkyl, 5- to 14-membered heteroaryl-C1-6 alkyl, (CH2)gSO2 (g = 1-8), (CH2)faCH:CH(CH2)fb (fa, fb = 0, 1,2,3), etc.; and Tg1 = a group of the general formula -Eg-CO-NRgl(Zg) or Q; wherein Eg = a single bond, (un)substituted NH; Rgl = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 aliphatic hydrocarbyl, etc.; Zg = C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl, etc.; Zg1, Zg2 = (a) a single bond, (b) C1-6 alkylene optionally having ≥1 atoms selected from O, S, and N in the middle or the terminus of the chain and optionally substituted with oxo, (c) (un)substituted C2-6 alkenyl] are prepared These compds. are also inhibitors of vascular endothelial growth factor receptor kinase (VEGFR2 kinase) and are useful as antitumor agents against hemangioma, pancreatic cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, lung cancer, brain tumor, leukemia, or ovarian cancer, as cancer metastasis inhibitors, and for the treatment of retina neovascularization, diabetic retinopathy, atherosclerosis, or inflammatory diseases such as osteoarthritis, rheumatoid arthritis, psoriasis, or delayed hypersensitivity. Thus, to solution of 334 mg 4-[6-(4-benzoyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenylamine in 4 mL DMF were added 0.066 mL pyridine and 0.102 mL Ph chlorocarbonate and stirred at room temperature for 2.5 h to give 330 mg N-[4-[6-(4-benzoyloxyphenyl)-7-(2- trimethylsilylethoxymethyl)-7H-

pyrrolo[2,3-d]pyrimidin-4-yloxy]-2- chlorophenyl]-N'-cyclopropylurea which (260 mg) was hydrogenolyzed over platinum oxide in ethanol overnight to give 160 mg N-[4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea (I). I showed IC₅₀ of 0.02 nM for inhibiting the vascular endothelial growth factor (VEGF)-stimulated sandwich tube formation in vascular endothelial cell.

IT 417716-92-8P 417719-50-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of urea derivs. containing nitrogenous aromatic ring compds.

as

angiogenesis inhibitors for prevention or treatment of diseases)

RN 417716-92-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



RN 417719-50-7 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

117

THERE ARE 117 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1354247 HCAPLUS Full-text

DOCUMENT NUMBER: 146:100576

TITLE: Preparation of amorphous salts of
4-[3-chloro-4-
[(cyclopropylaminocarbonyl)amino]phenoxy]-7-methoxy-6-

INVENTOR(S): Sakaguchi, Takahisa; Tsuruoka, Akihiko

PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan

SOURCE: PCT Int. Appl., 49pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006137474	A1	20061228	WO 2006-JP312487	20060622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006260148	A1	20061228	AU 2006-260148	20060622
CA 2606719	A1	20061228	CA 2006-2606719	20060622
US 20070004773	A1	20070104	US 2006-472372	20060622
US 7550483	B2	20090623		
EP 1894918	A1	20080305	EP 2006-767145	20060622
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
KR 2008008374	A	20080123	KR 2007-727079	20071121
CN 101233111	A	20080730	CN 2006-80020317	20071207
IN 2008CN00383	A	20080919	IN 2008-CN383	20080123
PRIORITY APPLN. INFO.:			US 2005-693044P	P 20050623
			WO 2006-JP312487	W 20060622
AB	This invention pertains to a method for producing amorphous salts of 4-[3-chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-methoxy-6-quinolinecarboxamide. The title compds. are useful as antitumor agents for various cancers, such as pancreas cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, lung cancer, renal cancer, brain cancer, blood cancer, ovarian cancer, and hemangioma (no data).			
IT	417716-92-8P RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of salts of 4-[3-chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-methoxy-6-quinolinecarboxamide as antitumor agents)			
RN	417716-92-8 HCAPLUS			

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy]-7-methoxy- (CA INDEX NAME)




IT 857890-31-4P 857890-33-6P 857890-35-8P
 857890-37-0P 857890-39-2P 857890-41-6P
 857890-45-0P 857890-47-2P 917572-43-1P
 917572-44-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of salts of
 4-[3-chloro-4-[[(cyclopropylaminocarbonyl) amino] phenoxy]-7-methoxy-6-
 quinolinecarboxamide as antitumor agents)


RN 857890-31-4 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy]-7-methoxy-, hydrochloride
 (1:1) (CA INDEX NAME)



RN 857890-33-6 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy]-7-methoxy-, hydrobromide (1:1)
 (CA INDEX NAME)



RN 857890-35-8 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy-,
 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8
 CMF C21 H19 Cl N4 O4



CM 2


CRN 104-15-4
 CMF C7 H8 O3 S



RN 857890-37-0 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, sulfate (1:1) (CA
 INDEX NAME)


CM 1

CRN 417716-92-8
 CMF C21 H19 Cl N4 O4



CM 2


CRN 7664-93-9
 CMF H2 O4 S



RN 857890-39-2 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate
 (1:1) (CA INDEX NAME)

CM 1


CRN 417716-92-8
 CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 857890-41-6 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate,
 hydrate (1:1:?) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 857890-45-0 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy] -7-methoxy-, acetate
 methanesulfonate (1:?:?) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4




CM 2

CRN 75-75-2

CMF C H4 O3 S




CM 3

CRN 64-19-7
CMF C2 H4 O2


RN 857890-47-2 HCAPLUS

CN Ethanesulfonic acid, compd. with 4-[3-chloro-4-
[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-
quinolinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8
CMF C21 H19 Cl N4 O4

CM 2

CRN 594-45-6
CMF C2 H6 O3 S


RN 917572-43-1 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate,
compd. with 1,1'-sulfinylbis[methane] (1:1:?) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2


CMF C H4 O3 S



CM 3

CRN 67-68-5

CMF C2 H6 O S




RN 917572-44-2 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, ethanesulfonate,
 compd. with 1,1'-sulfinylbis[methane] (1:1:?) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 594-45-6


CMF C2 H6 O3 S



CM 3

CRN 67-68-5

CMF C2 H6 O S



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:268466 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 144:324798
 TITLE: Simultaneous use of sulfonamide-containing compound and angiogenesis inhibitor
 INVENTOR(S): Owa, Takashi; Ozawa, Yoichi; Semba, Taro
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 270 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006030941	A1	20060323	WO 2005-JP17228	20050913
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006030947	A1	20060323	WO 2005-JP17238	20050913
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20060135486	A1	20060622	US 2005-226655	20050913
EP 1797877	A1	20070620	EP 2005-785820	20050913
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
US 20080286282	A1	20081120	US 2007-886214	20070827
PRIORITY APPLN. INFO.:			US 2004-609452P	P 20040913
			JP 2005-54150	A 20050228
			JP 2005-54475	A 20050228
			WO 2005-JP17238	W 20050913
			WO 2006-JP4208	W 20060228

OTHER SOURCE(S): MARPAT 144:324798

AB A pharmaceutical composition comprising a sulfonamide-containing compound combined with an angiogenesis inhibitor.


IT ~~417716-92-8~~, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide ~~417719-50-7~~

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sulfonamide-containing compds. and angiogenesis inhibitors for combination chemotherapy of ~~cancer~~)

RN 417716-92-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



RN 417719-50-7 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:612258 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:120562

TITLE: Crystal of salt of
4-[3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy]-
7-methoxy-6-quinolinecarboxamide or solvate thereof
and processes for producing these

INVENTOR(S): Matsushima, Tomohiro; Nakamura, Taiju; Yoshizawa,
Kazuhiro; Kamada, Atsushi; Ayata, Yusuke; Suzuki,
Naoko; Arimoto, Itaru; Sakaguchi, Takahisa; Gotoda,
Masaharu

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063713	A1	20050714	WO 2004-JP19223	20041222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004309217	A1	20050714	AU 2004-309217	20041222
AU 2004309217	B2	20081106		
CA 2543650	A1	20050714	CA 2004-2543650	20041222
EP 1698623	A1	20060906	EP 2004-807580	20041222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1890220	A	20070103	CN 2004-80036184	20041222
BR 2004018200	A	20070417	BR 2004-18200	20041222
RU 2328489	C2	20080710	RU 2006-126977	20041222
CN 101337931	A	20090107	CN 2008-10145600	20041222
CN 101337932	A	20090107	CN 2008-10145601	20041222
CN 101337933	A	20090107	CN 2008-10145602	20041222
US 20070078159	A1	20070405	US 2006-577531	20060428
MX 2006007256	A	20060823	MX 2006-7256	20060622
ZA 2006005226	A	20070425	ZA 2006-5226	20060623
KR 2006113759	A	20061102	KR 2006-713993	20060712
KR 804566	B1	20080220		
IN 2006CN02572	A	20070608	IN 2006-CN2572	20060713
KR 2007107185	A	20071106	KR 2007-722490	20071001
KR 870681	B1	20081126		
KR 2008028511	A	20080331	KR 2008-705282	20080303
KR 839554	B1	20080620		
PRIORITY APPLN. INFO.:			JP 2003-430939	A 20031225
			CN 2004-80036184	A3 20041222
			WO 2004-JP19223	W 20041222
			KR 2006-713993	A3 20060712
			KR 2007-722490	A3 20071001
AB	Disclosed are crystals of the hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate, or ethanesulfonate of 4-[3-chloro-4-(cyclopropylamino-carbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide or crystals of a solvate of any of these. The crystals have improved physicochem. and pharmacokinetic properties, and suitable for use as neovascularization inhibitors for treatment of related diseases.			
IT	857890-33-6P 857890-39-2P			
	RL: PEP (Physical, engineering or chemical process); PKT (Pharmacokinetics); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)			
	(crystal of salt of 4-[3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy]-7-methoxy-6-quinolinecarboxamide or solvate thereof as neovascularization inhibitor, and preparation thereof)			
RN	857890-33-6 HCAPLUS			
CN	6-Quinolinecarboxamide, 4-[3-chloro-4-			


[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, hydrobromide (1:1)
(CA INDEX NAME)



RN 857890-39-2 HCAPLUS
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate
(1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S



IT 857890-43-8P 857890-45-0P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

(crystal of salt of 4-[3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy]-7-methoxy-6-quinolinecarboxamide or solvate thereof as neovascularization inhibitor, and preparation thereof)


RN 857890-43-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-,
monomethanesulfonate, compd. with sulfonylbis[methane] (9CI) (CA INDEX
NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2


CMF C H4 O3 S



CM 3

CRN 67-71-0

CMF C2 H6 O2 S




RN 857890-45-0 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy]-7-methoxy-, acetate
 methanesulfonate (1:?:?) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2


CRN 75-75-2

CMF C H4 O3 S




CM 3

CRN 64-19-7
CMF C2 H4 O2




IT 857890-31-4P 857890-35-8P 857890-37-0P
857890-41-6P 857890-47-2P 857890-49-4P
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (crystal of salt of 4-[3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy]-7-methoxy-6-quinolinecarboxamide or solvate thereof as neovascularization inhibitor, and preparation thereof)
RN 857890-31-4 HCAPLUS
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



RN 857890-35-8 HCAPLUS
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 857890-37-0 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy]-7-methoxy-, sulfate (1:1) (CA
 INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 857890-41-6 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy] -7-methoxy-, methanesulfonate,
 hydrate (1:1:?) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 857890-47-2 HCAPLUS


CN Ethanesulfonic acid, compd. with 4-[3-chloro-4-

[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 594-45-6

CMF C2 H6 O3 S




RN 857890-49-4 HCAPLUS

CN Ethanesulfonic acid, compd. with 4-[3-chloro-4-[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide and sulfonylbis[methane] (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 594-45-6


CMF C2 H6 O3 S



CM 3

CRN 67-71-0


CMF C2 H6 O2 S



IT 417716-92-8P, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)amino-
phenoxy]-7-methoxy-6-quinolinecarboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(crystal of salt of 4-[3-chloro-4-(cyclopropylaminocarbonyl)amino-
phenoxy]-7-methoxy-6-quinolinecarboxamide or solvate thereof as
neovascularization inhibitor, and preparation thereof)

RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:1016020 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 141:427993
 TITLE: Polymorphous crystal of
 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-
 7-methoxy-6-quinolinecarboxamide and method for
 preparation thereof
 INVENTOR(S): Arimoto, Itaru; Yoshizawa, Kazuhiro; Kamada, Atsushi
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004101526	A1	20041125	WO 2004-JP5788	20040422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070117842	A1	20070524	US 2006-553927	20060630
PRIORITY APPLN. INFO.:			US 2003-464674P	P 20030422
			WO 2004-JP5788	W 20040422

AB Disclosed are a polymorphous crystal (A) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (I) having a diffraction peak at a diffraction angle ($2\theta \pm 0.2^\circ$) of 15.75° in the powder X-ray diffractometry; and a polymorphous crystal (B) of I having a


diffraction peak at a diffraction angle ($2\theta \pm 0.2^\circ$) of 21.75° in the powder X-ray diffractometry.

IT 417716-92-8P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide polymorphous crystals)

RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:314913 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 136:340689

TITLE: Preparation of urea derivatives containing nitrogenous aromatic ring compounds as inhibitors of angiogenesis

INVENTOR(S): Funahashi, Yasuhiro; Tsuruoka, Akihiko; Matsukura, Masayuki; Haneda, Toru; Fukuda, Yoshio; Kamata, Junichi; Takahashi, Keiko; Matsushima, Tomohiro; Miyazaki, Kazuki; Nomoto, Kenichi; Watanabe, Tatsuo; Obaishi, Hiroshi; Yamaguchi, Atsumi; Suzuki, Sachi; Nakamura, Katsuji; Mimura, Fusayo; Yamamoto, Yuji; Matsui, Junji; Matsui, Kenji; Yoshiba, Takako; Suzuki, Yasuyuki; Arimoto, Itaru

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 699 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032872	A1	20020425	WO 2001-JP9221	20011019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

US 10/797903

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2426461	A1	20020425	CA 2001-2426461	20011019
AU 2001095986	A	20020429	AU 2001-95986	20011019
HU 2003002603	A2	20031128	HU 2003-2603	20011019
CN 1478078	A	20040225	CN 2001-819710	20011019
CN 1308310	C	20070404		
EP 1415987	A1	20040506	EP 2001-976786	20011019
EP 1415987	B1	20070228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
EP 1506962	A2	20050216	EP 2004-25700	20011019
EP 1506962	A3	20050302		
EP 1506962	B1	20080702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
NZ 525324	A	20050324	NZ 2001-525324	20011019
JP 3712393	B2	20051102	JP 2002-536056	20011019
RU 2264389	C2	20051120	RU 2003-114740	20011019
AT 355275	T	20060315	AT 2001-976786	20011019
AU 2001295986	B2	20060817	AU 2001-295986	20011019
EP 1777218	A1	20070425	EP 2006-23078	20011019
EP 1777218	B1	20081231		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
CN 101024627	A	20070829	CN 2007-10007096	20011019
CN 101029022	A	20070905	CN 2007-10007097	20011019
ES 2282299	T3	20071016	ES 2001-976786	20011019
IL 155447	A	20080605	IL 2001-155447	20011019
AT 399766	T	20080715	AT 2004-25700	20011019
AT 419239	T	20090115	AT 2006-23078	20011019
ES 2318649	T3	20090501	ES 2006-23078	20011019
NO 2003001731	A	20030619	NO 2003-1731	20030414
MX 2003003362	A	20030801	MX 2003-3362	20030415
US 7253286	B2	20070807	US 2003-420466	20030418
US 20040053908	A1	20040318		
ZA 2003003567	A	20040810	ZA 2003-3567	20030508
JP 2005272474	A	20051006	JP 2005-124034	20050421
US 20060247259	A1	20061102	US 2005-293785	20051202
US 20060160832	A1	20060720	US 2006-347749	20060203
AU 2006203099	A1	20060810	AU 2006-203099	20060719
AU 2006236039	A1	20061207	AU 2006-236039	20061116
AU 2006236039	B2	20080522		
NO 2007004657	A	20030619	NO 2007-4657	20070912
PRIORITY APPLN. INFO.:				
			JP 2000-320420	A 20001020
			JP 2000-386195	A 20001220
			JP 2001-46685	A 20010222
			AU 2001-295986	A3 20011019
			AU 2001-95986	TO 20011019
			CN 2001-819710	A3 20011019
			EP 2001-976786	A3 20011019
			JP 2002-536056	A3 20011019

WO 2001-JP9221

W 20011019

US 2003-420466

A3 20030418


US 2005-293785

A1 20051202

OTHER SOURCE(S):

MARPAT 136:340689

GI



AB N-aryl or N-heteroarylurea derivs. represented by the general formula Ag-Xg-Yg-Tgl or salts thereof, or hydrates of both [wherein Ag = (un)substituted C6-14 aryl or 5- to 14-membered heterocyclic group; Xg = single bond, O, S, C1-6 alkylene, SO, SO₂, (un)substituted NH; Yg = (un)substituted C6-14 aryl, 5- to 14-membered heterocyclic group, C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl-C1-6 alkyl, 5- to 14-membered heteroaryl-C1-6 alkyl, (CH₂)_gSO₂ (g = 1-8), (CH₂)_{fa}CH:CH(CH₂)_{fb} (fa, fb = 0, 1,2,3), etc.; and Tgl = a group of the general formula -Eg-CO-NR_{g1}(Z_g) or Q; wherein Eg = a single bond, (un)substituted NH; R_{g1} = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 aliphatic hydrocarbyl, etc.; Z_g = C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl, etc.; Z_{g1}, Z_{g2} = (a) a single bond, (b) C1-6 alkylene optionally having ≥1 atoms selected from O, S, and N in the middle or the terminus of the chain and optionally substituted with oxo, (c) (un)substituted C2-6 alkenyl] are prepared These compds. are also inhibitors of vascular endothelial growth factor receptor kinase (VEGFR2 kinase) and are useful as antitumor agents against hemangioma, pancreatic cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, lung cancer, brain tumor, leukemia, or ovarian cancer, as cancer metastasis inhibitors, and for the treatment of retina neovascularization, diabetic retinopathy, atherosclerosis, or inflammatory diseases such as osteoarthritis, rheumatoid arthritis, psoriasis, or delayed hypersensitivity. Thus, to solution of 334 mg 4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yloxy]-2-chlorophenylamine in 4 mL DMF were added 0.066 mL pyridine and 0.102 mL Ph chlorocarbonate and stirred at room temperature for 2.5 h to give 330 mg N-[4-[6-(4-benzyloxyphenyl)-7-(2- trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2- chlorophenyl]-N'-cyclopropylurea which (260 mg) was hydrogenolyzed over platinum oxide in ethanol overnight to give 160 mg N-[4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea (I). I showed IC₅₀ of 0.02 nM for inhibiting the vascular endothelial growth factor (VEGF)-stimulated sandwich tube formation in vascular endothelial cell.

IT 417716-92-8P 417719-50-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of urea derivs. containing nitrogenous aromatic ring compds.


as

angiogenesis inhibitors for prevention or treatment of diseases)

RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-


[[(cyclopropylamino) carbonyl] amino] phenoxy] -7-methoxy- (CA INDEX NAME)



RN 417719-50-7 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d stat que 123
L1 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE

L3 107 SEA FILE=REGISTRY SSS FUL L1

L4 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE

L5 14 SEA FILE=REGISTRY SUB=L3 SSS FUL L4

L6 26 SEA FILE=HCAPLUS ABB=ON PLU=ON L5

L7 20506 SEA FILE=HCAPLUS ABB=ON PLU=ON ("SMALL-CELL LUNG CARCINOMA"/C
V OR "CARCINOMA (L) PULMONARY SMALL-CELL"/CV OR "LUNG (L)
SMALL-CELL CARCINOMA"/CV OR "LUNG, NEOPLASM (L) SMALL-CELL
CARCINOMA"/CV OR "LUNG OAT CELL CARCINOMA"/CV OR "LUNG SMALL
CELL CANCER"/CV) OR ("SMALL CELL CARCINOMA"/CV OR "SMALL CELL

LUNG CANCER"/CV OR "SMALL LUNG CELL CARCINOMA"/CV OR "SMALL-CELL
 L CARCINOMA (LUNG)"/CV OR "SMALL-CELL CARCINOMA (PULMONARY)"/CV
) OR SMALL(L)CELL(L)LUNG(L) (CANCER? OR CARCINOMA)
 L8 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 AND L7
 L9 22 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 NOT L8
 L10 18 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND (?CANCER? OR ?CARCIN?
 OR ?TUMOR? OR ?MALIG? OR ?NEOPLAS?)
 L11 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L10 AND (LUNG OR PULMON?)
 L12 2293 SEA FILE=HCAPLUS ABB=ON PLU=ON "YAMAMOTO Y"/AU OR YAMAMOTO Y
 ?/AU OR "YAMAMOTO YUJI"/AU
 L13 2815 SEA FILE=HCAPLUS ABB=ON PLU=ON "WATANABE T"/AU OR WATANABE T
 ?/AU OR ("WATANABE TATSUO"/AU OR "WATANABE TATSURO"/AU)
 L14 949 SEA FILE=HCAPLUS ABB=ON PLU=ON "OKADA M"/AU OR OKADA M ?/AU
 OR "OKADA MASAYUKI"/AU
 L15 41 SEA FILE=HCAPLUS ABB=ON PLU=ON "TSURUOKA A"/AU OR "TSURUOKA
 AKIHIKO"/AU
 L16 19 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15)
 L17 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15)
 L18 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND L15
 L19 93 SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT L5
 L20 16 SEA FILE=HCAPLUS ABB=ON PLU=ON L19
 L22 14 SEA FILE=HCAPLUS ABB=ON PLU=ON (L12 OR L13 OR L14 OR L15)
 AND (L6 OR L20)
 L23 23 SEA FILE=HCAPLUS ABB=ON PLU=ON ((L16 OR L17 OR L18) OR L22)
 NOT (L8 OR L11)


=> d ibib abs hitstr 123 1-23

L23 ANSWER 1 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009:464003 HCAPLUS Full-text
 TITLE: In-situ characterization of transport properties of
 superconducting (Cu, C)-1201 films
 AUTHOR(S): Kikunaga, K.; Yamamoto, Y.; Mitsunaga, M.; Mahara,
 Y.; Tanaka, Y.; Kikuchi, N.; Tokiwa, K.; Watanabe,
 T.; Terada, N.
 CORPORATE SOURCE: Department of Nano Structures and Advanced Materials,
 Kagoshima University, 1-21-40 Korimoto, Kagoshima,
 890-0065, Japan
 SOURCE: Journal of Physics: Conference Series (2009), 150, No
 pp. given
 CODEN: JPCSDZ; ISSN: 1742-6588
 URL: [http://www.iop.org/EJ/article/1742-
 6596/150/5/052108/jpconf9_150_052108.pdf](http://www.iop.org/EJ/article/1742-6596/150/5/052108/jpconf9_150_052108.pdf)
 PUBLISHER: Institute of Physics Publishing
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English
 AB Transport properties of (Cu, C)-1201 thin films have been characterized by in-
 situ four probe method without breaking vacuum, subsequent to their growth by
 pulsed laser deposition, in order to clarify intrinsic transport properties.
 Owing to the in-situ measurements, degradation of contact resistance and
 normal state conductivity were successfully suppressed. Obtained results
 reveal the pos. correlation between T_c and normal state conductivity σ at 290
 K, and that between T_c and temperature coefficient of resistivity (TCR) at 290
 K. The films exhibit $T_c(p = 0) > 20$ K on the cases of $\sigma[290 \text{ K}] > 4 \times 10^2 \text{ S/cm}$
 and $\text{TCR} > 1.5 \times 10^{-3} \text{ K}^{-1}$. The high T_c with low conductivity of (Cu, C)-1201
 films indicates the presence of extrinsic defects such as grain boundaries.
 The absence of saturation of T_c with an increase of TCR indicates doping level

of the (Cu, C)-1201 films in this study should be in between under-doped to optimally-doped states. They suggest there would be some room for further increases of Tc.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:945676 HCAPLUS Full-text
 DOCUMENT NUMBER: 150:70494
 TITLE: Anti-tumor effect of E7080, a novel angiogenesis inhibitor
 AUTHOR(S): Koyama, Noriyuki; Magario, Naoki; Yamamoto, Yuji; Matsui, Junji; Tsuruoka, Akihiko
 CORPORATE SOURCE: Clin. Res. Cent., Eisai Co., Ltd., Tokyo, 112-8088, Japan
 SOURCE: Nippon Yakurigaku Zasshi (2008), 132(2), 100-104
 CODEN: NYKZAU; ISSN: 0015-5691
 PUBLISHER: Nippon Yakuri Gakkai
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: Japanese
 AB A review on the inhibitory activity against angiogenesis and VEGF receptor kinase selectivity mechanism of E7080. Antitumor efficacies in preclin. study of E7080, mono- or combination with other neoplasm inhibitors are also discussed.
 IT 417716-92-8
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (E 7080; anti-tumor effect of E7080, novel angiogenesis inhibitor)
 RN 417716-92-8 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



L23 ANSWER 3 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:940616 HCAPLUS Full-text
 DOCUMENT NUMBER: 149:239320
 TITLE: Composition for treatment of undifferentiated-type of gastric cancer
 INVENTOR(S): Yamamoto, Yuji
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan

SOURCE: PCT Int. Appl., 221pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008093855	A1	20080807	WO 2008-JP51697	20080128
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2007-887006P P 20070129

OTHER SOURCE(S): MARPAT 149:239320

AB Disclosed are: a therapeutic agent, a kit and a treatment method for undifferentiated-type of gastric cancer; and a pharmaceutical composition, a kit and a treatment method which are more effective on a living body having at least one cell selected from the group consisting of a cell over-expressing FGFR2 and a cell expressing a FGFR2 mutant. A combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on undifferentiated-type of gastric cancer. The combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on a living body having at least one cell selected from the group consisting of a cell over-expressing FGFR2 and a cell expressing a FGFR2 mutant. For example, the synergistic effect of combination of 4-(3-chloro-4-[cyclopropylaminocarbonyl]aminophenoxy]-7-methoxy-6-quinolinecarboxamide and irinotecan hydrochloride in HSC-30 human gastric carcinoma cell-bearing mice was examined

IT 417716-92-8, 4-(3-Chloro-4-[cyclopropylaminocarbonyl]aminophenoxy]-7-methoxy-6-quinolinecarboxamide 417717-44-3, N6-Methoxy-4-(3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide 857890-39-2


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(composition for treatment of undifferentiated-type of gastric cancer containing

quinoline derivs. in combination with antitumor agent or FGFR2 inhibitor)


RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



RN 417717-44-3 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-N,7-dimethoxy- (CA INDEX
NAME)




RN 857890-39-2 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy-, methanesulfonate
(1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:890824 HCAPLUS Full-text
 DOCUMENT NUMBER: 149:167954
 TITLE: Composition for treatment of pancreatic cancer
 INVENTOR(S): Yamamoto, Yuji
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 126pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008088088	A1	20080724	WO 2008-JP51024	20080118
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,				

IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-885733P P 20070119
 US 2007-887010P P 20070129

OTHER SOURCE(S): MARPAT 149:167954


AB Disclosed are a pharmaceutical composition having excellent antitumor activity, and a method for treating a cancer. Specifically, excellent antitumor activity is achieved when 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (A) or an analogous compound thereof, a pharmacol. acceptable salt thereof or a solvate of any of them is used in combination with gemcitabine or erlotinib, a pharmacol. acceptable salt thereof or a solvate of any of them. For example, the effect of combination of a compound A 3 mg/kg and gemcitabine hydrochloride 200 mg/kg on AsPC-1 human pancreatic cancer cell-bearing mice was examined

IT 417716-92-8, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 417717-05-6,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide 417717-10-3,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide 417717-15-8,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide 417717-22-7,
 N6-Cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-23-8,
 N6-(2-Methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-35-2,
 N6-(2-Hydroxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-41-0,
 N6-(2-Fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-44-3,
 N6-Methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-76-1,
 N6-Methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-77-2,
 N6-Ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide 417718-41-3,
 N-(2-Fluoro-4-((6-carbamoyl-7-methoxy-4-[quinolyl]oxy)phenyl)-N'-cyclopropylurea 417719-21-2,
 4-(3-Fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417719-50-7,
 4-(3-Chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 417719-56-3,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide 417719-77-8,
 4-(3-Chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide 417719-84-7, N-(4-(6-(2-Cyanoethyl)carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N'-cyclopropylurea 417720-85-5,
 N6-Methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 857890-39-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pharmaceutical compns. containing urea derivs. in combination with
gemcitabine or erlotinib)


RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-(2-methoxyethoxy)- (CA
INDEX NAME)




RN 417717-07-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]-
(CA INDEX NAME)



RN 417717-10-3 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-(2-hydroxyethoxy)- (CA
INDEX NAME)



RN 417717-15-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 417717-22-7 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N-cyclopropyl-7-methoxy- (CA
 INDEX NAME)




RN 417717-23-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy-N-(2-methoxyethyl)-
 (CA INDEX NAME)




RN 417717-35-2 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N-(2-hydroxyethyl)-7-methoxy-
 (CA INDEX NAME)




RN 417717-41-0 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy] -N-(2-fluoroethyl) -7-methoxy-
(CA INDEX NAME)




RN 417717-44-3 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy] -N,7-dimethoxy- (CA INDEX
NAME)




RN 417717-76-1 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy-N-methyl- (CA INDEX
NAME)




RN 417717-77-2 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-N-ethyl-7-methoxy- (CA INDEX
NAME)




RN 417718-41-3 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[4-[[[(cyclopropylamino)carbonyl]amino]-3-fluorophenoxy]-7-methoxy- (CA INDEX NAME)



RN 417719-21-2 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[4-[[[(cyclopropylamino)carbonyl]amino]-3-fluorophenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)



RN 417719-50-7 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 417719-84-7 HCAPLUS

CN 6-Quinolinecarboxamide, N-(2-cyanoethyl)-4-[4-
[[(cyclopropylamino) carbonyl] amino]-3-fluorophenoxy]-7-methoxy- (CA INDEX
NAME)



RN 417720-85-5 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-(2-methoxyethoxy)-N-methyl-
(CA INDEX NAME)



RN 857890-39-2 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy]-7-methoxy-, methanesulfonate
 (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8
 CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2
 CMF C H4 O3 S




REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 5 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:281590 HCAPLUS Full-text
 DOCUMENT NUMBER: 148:323091
 TITLE: Antitumor agent for undifferentiated gastric cancer
 INVENTOR(S): Yamamoto, Yuji; Matsushima, Tomohiro; Tsuruoka, Akihiko; Obaishi, Hiroshi; Nakagawa, Takayuki
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 138pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008026748	A1	20080306	WO 2007-JP67088	20070827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2065372	A1	20090603	EP 2007-806561	20070827
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
KR 2009043578	A	20090506	KR 2009-705657	20090319
PRIORITY APPLN. INFO.:			JP 2006-230816	A 20060828
			WO 2007-JP67088	W 20070827
OTHER SOURCE(S):			MARPAT 148:323091	
GI				




AB A compound represented by the general formula (I), a pharmacol. acceptable salt thereof, or a solvate of the compound or the salt can exert its effect more effectively on undifferentiated gastric cancer, and can also exerts its effect more effectively on a living body having at least one member selected from the group consisting of a cell over-expressing FGFR2 and a cell expressing mutant FGFR2.


IT 417716-92-8P, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (quinolinylurea analogs as antitumor agents for undifferentiated gastric cancer)

RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




IT 417717-05-6, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-
 7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8
 417717-10-3 417717-15-8,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-
 dihydroxypropyl)oxy-6-quinolinecarboxamide 417717-22-7
 417717-23-8 417717-35-2 417717-41-0
 417717-44-3, N6-Methoxy-4-(3-chloro-4-
 (((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-
 quinolinecarboxamide 417717-76-1 417717-77-2
 417718-41-3 417719-21-2 417719-50-7
 417719-56-3 417719-77-8 417719-84-7
 417720-85-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (quinolinylurea analogs as antitumor agents for undifferentiated
 gastric cancer)
 RN 417717-05-6 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA
 INDEX NAME)




RN 417717-07-8 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]-

(CA INDEX NAME)



RN 417717-10-3 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-7-(2-hydroxyethoxy)- (CA
 INDEX NAME)



RN 417717-15-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 417717-22-7 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy] -N-cyclopropyl-7-methoxy- (CA
INDEX NAME)




RN 417717-23-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy] -7-methoxy-N-(2-methoxyethyl)-
(CA INDEX NAME)




RN 417717-35-2 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N-(2-hydroxyethyl)-7-methoxy-
 (CA INDEX NAME)



RN 417717-41-0 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N-(2-fluoroethyl)-7-methoxy-
 (CA INDEX NAME)




RN 417717-44-3 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N,7-dimethoxy- (CA INDEX
 NAME)




RN 417717-76-1 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-methoxy-N-methyl- (CA INDEX
NAME)




RN 417717-77-2 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino] phenoxy]-N-ethyl-7-methoxy- (CA INDEX
NAME)




RN 417718-41-3 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[4-[[[(cyclopropylamino)carbonyl]amino]-3-fluorophenoxy]-7-methoxy- (CA INDEX NAME)



RN 417719-21-2 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[4-[[[(cyclopropylamino)carbonyl]amino]-3-fluorophenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)



RN 417719-50-7 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 417719-84-7 HCAPLUS

CN 6-Quinolinecarboxamide, N-(2-cyanoethyl)-4-[4-
[[(cyclopropylamino) carbonyl] amino]-3-fluorophenoxy]-7-methoxy- (CA INDEX
NAME)



RN 417720-85-5 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-(2-methoxyethoxy)-N-methyl-
(CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:509696 HCAPLUS Full-text
 DOCUMENT NUMBER: 146:455231
 TITLE: Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
 INVENTOR(S): Yamamoto, Yuji
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 102pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007052850	A1	20070510	WO 2006-JP322516	20061107
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1949902	A1	20080730	EP 2006-832529	20061107
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRIORITY APPLN. INFO.:			JP 2005-322946	A 20051107
			WO 2006-JP322516	W 20061107

OTHER SOURCE(S): MARPAT 146:455231

AB Disclosed are a pharmaceutical composition having an excellent anti-tumor effect, and a therapeutic method for cancer. 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analog thereof can be used in combination with a substance having a c-kit kinase-inhibiting activity to produce an excellent anti-tumor effect. For example, the effect of combination of 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate and imatinib on human gastrointestinal stromal tumor cell (GIST882 cell)-bearing model mice was examined


IT 417716-92-8, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide 417717-05-6, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-[2-(4-morpholino)ethoxy-6-quinolinecarboxamide 417717-10-3, 4-(3-Chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide 417717-15-8,

4-(3-Chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-[(2S)-2,3-dihydroxypropyl]oxy-6-quinolinecarboxamide 417717-22-7,
 N6-Cyclopropyl-4-(3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-23-8,
 N6-(2-Methoxyethyl)-4-(3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-35-2,
 N6-(2-Hydroxyethyl)-4-(3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-41-0,
 N6-(2-Fluoroethyl)-4-(3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-44-3,
 N6-Methoxy-4-(3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-76-1,
 N6-Methyl-4-(3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-77-2,
 N6-Ethyl-4-(3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy)-7-methoxy-6-quinolinecarboxamide 417718-41-3,
 N-[2-Fluoro-4-[(6-carbamoyl-7-methoxy-4-quinolyl)oxy]phenyl]-N'-cyclopropylurea 417719-21-2,
 4-(3-Fluoro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417719-50-7,
 4-[3-Chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide 417719-56-3,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide 417719-77-8,
 4-[3-Chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidino)propoxy]-6-quinolinecarboxamide 417719-84-7, N-[4-[6-(2-Cyanoethyl)carbamoyl-7-methoxy-4-quinolyl]oxy]-2-fluorophenyl]-N'-cyclopropylurea 417720-85-5,
 N6-Methyl-4-(3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 857890-39-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(use of combination of anti-angiogenic substance and c-kit kinase inhibitor)

RN 417716-92-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy] -7-(2-methoxyethoxy) - (CA
 INDEX NAME)



RN 417717-07-8 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy] -7-[2-(4-morpholinyl) ethoxy] -
 (CA INDEX NAME)




RN 417717-10-3 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy] -7-(2-hydroxyethoxy) - (CA
 INDEX NAME)



RN 417717-15-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 417717-22-7 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-N-cyclopropyl-7-methoxy- (CA
INDEX NAME)




RN 417717-23-8 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy-N-(2-methoxyethyl)-
 (CA INDEX NAME)



RN 417717-35-2 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N-(2-hydroxyethyl)-7-methoxy-
 (CA INDEX NAME)




RN 417717-41-0 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N-(2-fluoroethyl)-7-methoxy-
 (CA INDEX NAME)




RN 417717-44-3 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-N,7-dimethoxy- (CA INDEX
NAME)




RN 417717-76-1 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy-N-methyl- (CA INDEX
NAME)




RN 417717-77-2 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[[(cyclopropylamino)carbonyl]amino]phenoxy]-N-ethyl-7-methoxy- (CA INDEX
NAME)




RN 417718-41-3 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[4-[[[(cyclopropylamino)carbonyl]amino]-3-
fluorophenoxy]-7-methoxy- (CA INDEX NAME)



RN 417719-21-2 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[4-[[[(cyclopropylamino)carbonyl]amino]-3-fluorophenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)



RN 417719-50-7 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy] -7-(2-ethoxyethoxy)- (CA INDEX
 NAME)



RN 417719-77-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy] -7-[(2R)-2-hydroxy-3-(1-
 pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 417719-84-7 HCAPLUS

CN 6-Quinolinecarboxamide, N-(2-cyanoethyl)-4-[4-
 [[(cyclopropylamino) carbonyl] amino] -3-fluorophenoxy] -7-methoxy- (CA INDEX
 NAME)



RN 417720-85-5 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-(2-methoxyethoxy)-N-methyl-
(CA INDEX NAME)




RN 857890-39-2 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy-, methanesulfonate
(1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 7 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:509694 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 146:455230
 TITLE: Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
 INVENTOR(S): Yamamoto, Yuji
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 103pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007052849	A1	20070510	WO 2006-JP322514	20061107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

AU 2006309551	A1	20070510	AU 2006-309551	20061107
CA 2627598	A1	20070510	CA 2006-2627598	20061107
US 20090053236	A1	20090226	US 2008-92539	20080502
CN 101316590	A	20081203	CN 2006-80041355	20080506
KR 2008065698	A	20080714	KR 2008-713685	20080605

PRIORITY APPLN. INFO.:

JP 2005-322946	A	20051107
WO 2006-JP322514	W	20061107

OTHER SOURCE(S): MARPAT 146:455230

AB Disclosed are a pharmaceutical composition having an excellent anti-tumor effect, and a therapeutic method for cancer. 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analog thereof can be used in combination with a substance having a c-kit kinase-inhibiting activity to produce an excellent anti-tumor effect. For example, the effect of combination of 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate and imatinib on human gastrointestinal stromal tumor cell (GIST882 cell)-bearing model mice was examined

IT 417716-92-8, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide 417717-05-6, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-[2-(4-morpholino)ethoxy-6-quinolinecarboxamide 417717-10-3, 4-(3-Chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)-6-quinolinecarboxamide 417717-15-8, 4-(3-Chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy)-7-[(2S)-2,3-dihydroxypropyl]oxy-6-quinolinecarboxamide 417717-22-7, N6-Cyclopropyl-4-(3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-23-8, N6-(2-Methoxyethyl)-4-(3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-35-2, N6-(2-Hydroxyethyl)-4-(3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-41-0, N6-(2-Fluoroethyl)-4-(3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-44-3, N6-Methoxy-4-(3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-76-1, N6-Methyl-4-(3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy)-7-methoxy-6-quinolinecarboxamide 417717-77-2, N6-Ethyl-4-(3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy)-7-methoxy-6-quinolinecarboxamide 417718-41-3, N-[2-Fluoro-4-[(6-carbamoyl-7-methoxy-4-quinolyl)oxy]phenyl]-N'-cyclopropylurea 417719-21-2, 4-(3-Fluoro-4-[(cyclopropylamino)carbonyl]amino]phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417719-50-7, 4-[3-Chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide 417719-56-3, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide 417719-77-8,


4-[3-Chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidino)propoxy]-6-quinolinecarboxamide
 417719-84-7, N-[4-[6-(2-Cyanoethyl) carbamoyl-7-methoxy-4-quinolyl]oxy]-2-fluorophenyl]-N'-cyclopropylurea 417720-85-5,
 N6-Methyl-4-(3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 857890-39-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of combination of anti-angiogenic substance and c-kit kinase inhibitor)


RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)




RN 417717-07-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 417717-10-3 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-7-(2-hydroxyethoxy)- (CA
 INDEX NAME)



RN 417717-15-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 417717-22-7 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[[(cyclopropylamino)carbonyl]amino]phenoxy]-N-cyclopropyl-7-methoxy- (CA
INDEX NAME)




RN 417717-23-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-N-(2-methoxyethyl)-
(CA INDEX NAME)




RN 417717-35-2 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N-(2-hydroxyethyl)-7-methoxy-
 (CA INDEX NAME)



RN 417717-41-0 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N-(2-fluoroethyl)-7-methoxy-
 (CA INDEX NAME)




RN 417717-44-3 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N,7-dimethoxy- (CA INDEX
 NAME)




RN 417717-76-1 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy-N-methyl- (CA INDEX
NAME)




RN 417717-77-2 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-N-ethyl-7-methoxy- (CA INDEX
NAME)




RN 417718-41-3 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[4-[[[(cyclopropylamino)carbonyl]amino]-3-fluorophenoxy]-7-methoxy- (CA INDEX NAME)



RN 417719-21-2 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[4-[[[(cyclopropylamino)carbonyl]amino]-3-fluorophenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)



RN 417719-50-7 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 417719-84-7 HCAPLUS

CN 6-Quinolinecarboxamide, N-(2-cyanoethyl)-4-[4-
[[(cyclopropylamino) carbonyl] amino]-3-fluorophenoxy]-7-methoxy- (CA INDEX
NAME)



RN 417720-85-5 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-(2-methoxyethoxy)-N-methyl-
(CA INDEX NAME)



RN 857890-39-2 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate
 (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8
 CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2
 CMF C H4 O3 S




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 8 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:150229 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 146:221063
 TITLE: Method for assaying anti-tumor effect of angiogenesis inhibitor
 INVENTOR(S): Uenaka, Toshimitsu; Yamamoto, Yuji; Matsui, Junji
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 147pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007015578	A1	20070208	WO 2006-JP315698	20060802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1925676	A1	20080528	EP 2006-768437	20060802
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRIORITY APPLN. INFO.:			JP 2005-224173	A 20050802
			JP 2006-164700	A 20060614
			WO 2006-JP315698	W 20060802
OTHER SOURCE(S): MARPAT 146:221063				
AB	Disclosed is a method for predicting the anti-tumor effect of an angiogenesis inhibitor. The method comprises evaluating the EGF-dependence property of an angiogenesis inhibitor with respect to proliferation and/or survival of tumor cells, and using the evaluated EGF-dependence property as a measure. The anti-tumor effect of an angiogenesis inhibitor correlates with the EGF-dependency property of the inhibitor with respect to proliferation and/or survival of tumor cells. Therefore, an angiogenesis inhibitor is capable of exerting an excellent anti-tumor effect by using it in combination with a substance having an EGF inhibitory effect.			
IT	417716-92-8 , 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 417716-92-8D , 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, pharmacol. allowed salt, solvate 417717-05-6 , 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8 417717-10-3 417717-15-8 417717-22-7 417717-23-8 417717-35-2 417717-41-0 417717-44-3 417717-76-1 417717-77-2 417718-41-3 417719-21-2 417719-50-7 417719-56-3 417719-77-8 417719-84-7 417720-85-5 857890-39-2 RL: ANT (Analyte); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (method for assaying anti-tumor effect of angiogenesis inhibitor by evaluating EGF-dependency)			
RN	417716-92-8 HCAPLUS			
CN	6-Quinolinecarboxamide, 4-[3-chloro-4- [[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)			




RN 417716-92-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-(2-methoxyethoxy)- (CA
INDEX NAME)




RN 417717-07-8 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-[2-(4-morpholinyl) ethoxy]-
(CA INDEX NAME)



RN 417717-10-3 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino] phenoxy]-7-(2-hydroxyethoxy)- (CA
INDEX NAME)



RN 417717-15-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 417717-22-7 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N-cyclopropyl-7-methoxy- (CA
 INDEX NAME)




RN 417717-23-8 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy-N-(2-methoxyethyl)-
 (CA INDEX NAME)




RN 417717-35-2 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N-(2-hydroxyethyl)-7-methoxy-
 (CA INDEX NAME)




RN 417717-41-0 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N-(2-fluoroethyl)-7-methoxy-
 (CA INDEX NAME)



RN 417717-44-3 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-N,7-dimethoxy- (CA INDEX
 NAME)




RN 417717-76-1 HCAPLUS
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy-N-methyl- (CA INDEX
 NAME)




RN 417717-77-2 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[[(cyclopropylamino)carbonyl]amino]phenoxy]-N-ethyl-7-methoxy- (CA INDEX
NAME)




RN 417718-41-3 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[4-[[[(cyclopropylamino)carbonyl]amino]-3-
fluorophenoxy]-7-methoxy- (CA INDEX NAME)



RN 417719-21-2 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[4-[[[(cyclopropylamino)carbonyl]amino]-3-fluorophenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)



RN 417719-50-7 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX
 NAME)



RN 417719-77-8 HCAPLUS


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
 [[(cyclopropylamino) carbonyl] amino] phenoxy]-7-[(2R)-2-hydroxy-3-(1-
 pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 417719-84-7 HCAPLUS

CN 6-Quinolinecarboxamide, N-(2-cyanoethyl)-4-[4-
 [[(cyclopropylamino) carbonyl] amino]-3-fluorophenoxy]-7-methoxy- (CA INDEX
 NAME)



RN 417720-85-5 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-(2-methoxyethoxy)-N-methyl-
(CA INDEX NAME)




RN 857890-39-2 HCAPLUS

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-
[[(cyclopropylamino) carbonyl] amino]phenoxy]-7-methoxy-, methanesulfonate
(1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 9 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:583343 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:248650

TITLE: Synthesis of Morphiceptin (Tyr-Pro-Phe-Pro-NH₂) by Dipeptidyl Aminopeptidase IV Derived from *Aspergillus oryzae*

AUTHOR(S): Ota, Toru; Itoh, Aki; Tachi, Hiroshi; Kudoh, Keita; Watanabe, Tatsuo; Yamamoto, Yuji; Tadokoro, Tadahiro; Maekawa, Akio

CORPORATE SOURCE: Department of Human Life and Development, Nayoro City College, Nayoro, Hokkaido, 096-8641, Japan

SOURCE: Journal of Agricultural and Food Chemistry (2005), 53(15), 6112-6116

CODEN: JAFCAU; ISSN: 0021-8561

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:248650

AB Morphiceptin (H-Tyr-Pro-Phe-Pro-NH₂) was synthesized using dipeptidyl aminopeptidase IV (DPIV, EC 3.4.14.5; derived from *Aspergillus oryzae* RIB 915) as a peptide coupling catalyst. H-Tyr-Pro-OEt·HCl was incubated with H-Phe-Pro-NH₂·HCl in the presence of DPIV under various conditions of temperature, concns. of ethylene glycol, pH, and reaction time. Morphiceptin was obtained at 40% yield under the optimal reaction conditions: substrates, 4 mM H-Tyr-

Pro-OEt·HCl and 20 mM H-Phe-Pro-NH₂·HCl; enzyme, DPIP, 0.275 nkat; solvent, 60% ethylene glycol containing 20 mM phosphate buffer at pH 7.0; 4.2 mM diisopropylamine at 4° for 24 h. Amino group protection was unnecessary for this enzymic synthesis of morphiceptin.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 10 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:529441 HCAPLUS Full-text

DOCUMENT NUMBER: 143:278018

TITLE: Recent progress of angiogenesis inhibitors

AUTHOR(S): Watanabe, Tatsuo; Tsuruoka, Akihiko

CORPORATE SOURCE: Clinical Research Center, New Product Development
Dep., Eisai Co., Ltd., Bunkyo-ku, Tokyo, 112-8088,
Japan

SOURCE: Saibo (2005), 37(4), 156-159

CODEN: SAIBC7; ISSN: 1346-7557

PUBLISHER: Nyu Saiensusha

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

AB A review, discussing recent progress of angiogenesis inhibitors as antitumor agents by targeting VEGF and its receptors.

L23 ANSWER 11 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:374114 HCAPLUS Full-text

DOCUMENT NUMBER: 143:33629

TITLE: K0 photoproduction on ¹²C in the threshold region

AUTHOR(S): Watanabe, T.; Endo, S.; Fujii, Y.; Hashimoto, O.;
Hirose, K.; Ishikawa, T.; Ito, K.; Kanda, H.; Katoh,
M.; Kinoshita, T.; Konno, O.; Maeda, K.; Matsumura,
A.; Miura, Y.; Miyahara, F.; Miyase, H.; Mizunuma, K.;
Nakabayashi, T.; Nakamura, S. N.; Nomura, H.; Okayasu,
Y.; Osaka, T.; Otani, A.; Oyamada, M.; Sasaki, A.;
Sato, T.; Shimizu, H.; Takahashi, T.; Tamae, T.;
Tamura, H.; Terasawa, T.; Tsubota, H.; Tsukada, K.;
Ukai, M.; Utoyama, M.; Wakamatsu, M.; Yamauchi, H.;
Yamaguchi, Y.; Yamamoto, Y.; Yamazaki, H.

CORPORATE SOURCE: Department of Physics, Tohoku University, Sendai,
980-8578, Japan

SOURCE: Nuclear Physics A (2005), A754, 327c-331c

CODEN: NUPABL; ISSN: 0375-9474

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The $\gamma n \rightarrow K0\Lambda$ process plays an important role in the study of strangeness production by the electromagnetic interaction. We have investigated the quasi-free production reaction on a ¹²C target in the threshold region ($E_\gamma = 0.8$ – 1.1 GeV) at the Laboratory of Nuclear Science, Tohoku University. Preliminary results are presented.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 12 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:20255 HCAPLUS Full-text

DOCUMENT NUMBER: 138:113464

TITLE: Photoproduction of neutral kaons on carbon in the threshold region

AUTHOR(S): Takahashi, T.; Watanabe, T.; Tsukada, K.; Kanda, H.; Itoh, K.; Wakamatsu, M.; Yamazaki, H.; Kinoshita, T.; Ukai, M.; Osaka, T.; Mizunuma, K.; Yamamoto, Y.; Tamae, T.; Nakamura, S. N.; Fujii, Y.; Maeda, K.; Miyase, H.; Tsubota, H.; Tamura, H.; Kato, M.; Konno, O.; Sasaki, A.; Terasawa, T.; Hashimoto, O.

CORPORATE SOURCE: Dep. Phys., Tohoku Univ., Sendai, 980-8578, Japan

SOURCE: Kakuriken Kenkyu Hokoku (Tohoku Daigaku) (2002), 35, 30-33

CODEN: TLNRBV; ISSN: 0385-2105

PUBLISHER: Tohoku Daigaku Daigakuin Rigaku Kenkyuka Fuzoku

Genshikaku Rigaku Kenkyu Shisetsu

DOCUMENT TYPE: Journal

LANGUAGE: English

AB New data of the photoprod. of the different iso-spin channels or spins observable are required. This proj. aims to measure $\gamma + n \rightarrow K0 + \Lambda$ channel at the threshold region. As a 1st step of the expts., quasi-free production on C were measured. The present status of the spectrometer and anal. are reported on. The K0 is measured by detecting and reconstructing, $K0s \rightarrow \pi^+ + \pi^-$ decay with the NKS (Neutral Kaon Spectrometer). The horizontal momentum of charged particles is determined by reconstructing the trajectory using the SDC (Straw Drift Chamber) and CDC (Cylindrical Drift Chamber) and Inverse of the velocity vs. momentum of the charged tracks.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 13 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:859508 HCAPLUS Full-text

DOCUMENT NUMBER: 138:378719

TITLE: Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin $\alpha 2$ subunit on endothelium

AUTHOR(S): Funahashi, Yasuhiro; Sugi, Naoko Hata; Semba, Taro; Yamamoto, Yuji; Hamaoka, Shinichi; Tsukahara-Tamai, Naoko; Ozawa, Yoichi; Tsuruoka, Akihiko; Nara, Kazumasa; Takahashi, Keiko; Okabe, Tadashi; Kamata, Junichi; Owa, Takashi; Ueda, Norihiro; Haneda, Toru; Yonaga, Masahiro; Yoshimatsu, Kentaro; Wakabayashi, Toshiaki

CORPORATE SOURCE: Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, 300-2635, Japan

SOURCE: Cancer Research (2002), 62(21), 6116-6123

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In the process of angiogenesis, endothelial adhesion mols. play a significant role in vascular morphogenesis, in coordination with angiogenic factor signaling. Here we report that a novel angiogenesis inhibitor, E7820 (an aromatic sulfonamide derivative), inhibited in vitro proliferation and tube formation of human umbilical vascular endothelial cell (HUVEC). E7820 decreased integrin $\alpha 2$, 3, 5, and $\beta 1$ in confluent culture of HUVEC, and integrin $\alpha 2$ was initially suppressed in mRNA level, followed by decrement of integrins $\alpha 3$, 5, and $\beta 1$. The inhibition of integrin $\alpha 2$ expression in HUVEC showed dose dependence but did not alter the level of CD31. Up-regulation of integrin $\alpha 2$ by phorbol 12-myristate 13-acetate abrogated the inhibitory effect of E7820 on tube formation within type I collagen gel, whereas addition of

antibody against integrin $\alpha 2$ canceled the phorbol 12-myristate 13-acetate effect. These results suggest that E7820 inhibited tube formation through the suppression of integrin $\alpha 2$. Oral administration of E7820 remarkably resulted in inhibition of tumor-induced angiogenesis in mouse dorsal air sac model, and tumor growth of human colorectal tumor cell lines (WiDr and LoVo) was inhibited in xenotransplanted model in mice. This is the first time that a small mol. has been shown to modulate integrins, and this finding may provide the basis for a new approach to antiangiogenic therapy through the suppression of integrin $\alpha 2$ on endothelium.

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 14 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:581738 HCAPLUS Full-text

DOCUMENT NUMBER: 135:175421

TITLE: Integrin expression inhibitors

INVENTOR(S): Wakabayashi, Toshiaki; Funahashi, Yasuhiro; Hata, Naoko; Semba, Taro; Yamamoto, Yuji; Haneda, Toru; Owa, Takashi; Tsuruoka, Akihiko; Kamata, Junichi; Okabe, Tadashi; Takahashi, Keiko; Nara, Kazumasa; Hamaoka, Shinichi; Ueda, Norihiro

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056607	A1	20010809	WO 2001-JP713	20010201
W: AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2399001	A1	20010809	CA 2001-2399001	20010201
AU 2001028867	A	20010814	AU 2001-28867	20010201
AU 781506	B2	20050526		
EP 1258252	A1	20021120	EP 2001-948941	20010201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
HU 2003000544	A2	20030728	HU 2003-544	20010201
HU 2003000544	A3	20050329		
NZ 520299	A	20040528	NZ 2001-520299	20010201
RU 2240826	C2	20041127	RU 2002-123580	20010201
CN 100356979	C	20071226	CN 2001-804388	20010201
JP 4039856	B2	20080130	JP 2001-556505	20010201
US 20040018192	A1	20040129	US 2002-181562	20020718
MX 2002007249	A	20021209	MX 2002-7249	20020725
KR 767000	B1	20071015	KR 2002-709945	20020801
NO 2002003688	A	20021003	NO 2002-3688	20020802
US 20050176712	A1	20050811	US 2005-97218	20050404
KR 767002	B1	20071015	KR 2007-701761	20070124
PRIORITY APPLN. INFO.:			JP 2000-26080	A 20000203
			JP 2000-402084	A 20001228
			WO 2001-JP713	W 20010201
			US 2002-181562	A1 20020718
			KR 2002-709945	A3 20020801

OTHER SOURCE(S): MARPAT 135:175421

AB Integrin expression inhibitors and remedies for arteriosclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinitis or inflammatory diseases, anticoagulant agents and cancerous metastasis inhibitors based on the integrin inhibitory effect. Namely, integrin expression inhibitors containing as the active ingredient sulfonamide compds. represented by the following general formula $\text{BKSO}_2\text{N(R1)ZR}$, pharmacol. acceptable salts thereof or hydrates of the same wherein B represents optionally substituted C6-10 aryl or 6- to 10-membered heteroaryl wherein the ring may be partly saturated; K represents a single bond, $-\text{CH}=\text{CH}-$ or $-(\text{CR}_4\text{bR}_5\text{b})\text{mb}-$ (wherein R_4b and R_5b may be the same or different and each represents hydrogen or C1-4 alkyl; and mb represents an integer of 1 or 2); R_1 represents hydrogen or C1-6 alkyl; Z represents a single bond or $\text{CO-NH}-$; and R represents optionally substituted C6-10 aryl or 6- to 10-membered heteroaryl wherein the ring may be partly saturated

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 15 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:563144 HCAPLUS Full-text

DOCUMENT NUMBER: 135:283445

TITLE: Mice lacking histidine decarboxylase exhibit abnormal mast cells

AUTHOR(S): Ohtsu, H.; Tanaka, S.; Terui, T.; Hori, Y.; Makabe-Kobayashi, Y.; Pejler, G.; Tchougounova, E.; Hellman, L.; Gertsenstein, M.; Hirasawa, N.; Sakurai, E.; Buzas, E.; Kovacs, P.; Csaba, G.; Kittel, A.; Okada, M.; Hara, M.; Mar, L.; Numayama-Tsuruta, K.; Ishigaki-Suzuki, S.; Ohuchi, K.; Ichikawa, A.; Falus, A.; Watanabe, T.; Nagy, A.

CORPORATE SOURCE: Department of Cellular Pharmacology, Tohoku University School of Medicine, Aoba-ku, Sendai, 980-8575, Japan

SOURCE: FEBS Letters (2001), 502(1,2), 53-56

CODEN: FEBLAL; ISSN: 0014-5793

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Histidine decarboxylase (HDC) synthesizes histamine from histidine in mammals. To evaluate the role of histamine, we generated HDC-deficient mice using a gene targeting method. The mice showed a histamine deficiency and lacked histamine-synthesizing activity from histidine. These HDC-deficient mice are viable and fertile but exhibit a decrease in the nos. of mast cells while the remaining mast cells show an altered morphol. and reduced granular content. The amts. of mast cell granular proteases were tremendously reduced. The HDC-deficient mice provide a unique and promising model for studying the role of histamine in a broad range of normal and disease processes.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 16 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:489373 HCAPLUS Full-text



DOCUMENT NUMBER: 135:76882

TITLE: Preparation of heterocyclic compounds having sulfonamide groups as inhibitors of angiogenesis

INVENTOR(S): Haneda, Toru; Tsuruoka, Akihiko; Kamata, Junichi; Okabe, Tadashi; Takahashi, Keiko; Nara, Kazumasa; Hamaoka, Shinichi; Ueda, Norihiro; Wakabayashi, Toshiaki; Funahashi, Yasuhiro; Semba, Taro; Hata, Naoko; Yamamoto, Yuji; Ozawa, Yoichi; Tsukahara,

Naoko; Owa, Takashi
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047891	A1	20010705	WO 2000-JP9326	20001227
W: AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2395772	A1	20010705	CA 2000-2395772	20001227
AU 2001022283	A	20010709	AU 2001-22283	20001227
AU 776933	B2	20040923		
EP 1243583	A1	20020925	EP 2000-985953	20001227
EP 1243583	B1	20050928		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
HU 2002003973	A2	20030328	HU 2002-3973	20001227
HU 2002003973	A3	20040728		
NZ 519380	A	20041029	NZ 2000-519380	20001227
RU 2239631	C2	20041110	RU 2002-120515	20001227
CN 1217936	C	20050907	CN 2000-818005	20001227
AT 305302	T	20051015	AT 2000-985953	20001227
ES 2246922	T3	20060301	ES 2000-985953	20001227
JP 4234344	B2	20090304	JP 2001-549363	20001227
US 20030144507	A1	20030731	US 2002-149253	20020610
US 6787534	B2	20040907		
NO 324268	B1	20070917	NO 2002-3097	20020626
MX 2002006474	A	20021129	MX 2002-6474	20020627
PRIORITY APPLN. INFO.:			JP 1999-375489	A 19991228
			WO 2000-JP9326	W 20001227
OTHER SOURCE(S):	CASREACT 135:76882; MARPAT 135:76882			
GI				

Q¹=

AB Heterocyclic compds. having sulfonamide or sulfonylurea groups, specifically heterocyclic compds. of general formula (I), pharmacol. acceptable salts of the same, or hydrates of both [wherein A is hydrogen, halogeno, optionally halogenated C1-4 alkyl, hydroxy, cyano, (CO)kNR₂R₃, or optionally substituted C2-4 alkenyl or alkynyl (wherein R₂ and R₃ are each independently hydrogen or optionally halogenated C1-4 alkyl; k is 0 or 1); B is optionally substituted aryl, monocyclic heteroaryl, or Q¹ (wherein the ring Q is an optionally substituted aromatic ring containing 1 or 2 N atoms; the ring M is optionally substituted and unsatd. C5-12 monocyclic or polycyclic ring sharing a double

bond with the ring Q and optionally containing 1-4 heteroatom selected from N, O, and S; the ring Q and M may share a N atom); K is a single bond or (CR4R5)m (wherein R4 and R5 are each independently hydrogen or C1-4 alkyl; m is 1 or 2); T, W, X and Y are each independently =C(D)- (wherein D is hydrogen, halogeno, hydroxy, C1-4 alkyl, halo-C1-4 alkyl, or the like) or nitrogen; U and V are each independently =C(D)-, nitrogen, oxygen, or CO; Z is a single bond or -CONH-; and R1 is hydrogen or C1-4 alkyl] are prepared These compds. includes N-quinolinylpyridinesulfonamides, N-quinolinylbenzenesulfonamides, N-quinolinylquinolinesulfonamides, N-quinolinylindolinesulfonamides, N-quinolinylisoquinolinesulfonamides, N-quinolinylbenzofuransulfonamides, N-quinolinyltetrahydronaphthalanesulfonamides, N-quinolinylbenzoxathiansulfonamide, N-quinolinylbenzothiopyransulfonamide, N-isoquinolinylpyridinesulfonamides, N-isoquinolinylbenzenesulfonamides, N-naphthyridinylpyridinesulfonamides, N-naphthyridinylbenzenesulfonamides, N-quinolinylpyridazinesulfonamides, etc. They are useful as therapeutics based on angiogenesis inhibition such as antitumor agents, cancer metastasis inhibitors, and therapeutics for diabetic retinopathy, rheumatic arthritis, and hemangioma. Thus, 5-indansulfonyl chloride was added to a solution of 3-amino-8-bromoquinoline in pyridine and stirred at room temperature for 30 min to give N-(8-bromoquinolin-3-yl)-5-indansulfonamide (II). II and N-(8-bromoquinolin-3-yl)-6-methoxypyridazine-3-sulfonamide in vitro showed IC50 of 0.04 and 0.53 µg/mL, resp., against angiogenesis in rat aorta.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 17 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:608721 HCAPLUS Full-text

DOCUMENT NUMBER: 133:193071

TITLE: Preparation of sulfonamide-containing indole derivatives as inhibitors of neovascularization and tumor

INVENTOR(S): Haneda, Toru; Tsuruoka, Akihiko; Kamata, Junichi; Okabe, Tadashi; Takahashi, Keiko; Nara, Kazumasa; Hamaoka, Shinichi; Ueda, Norihiro; Ohwa, Takashi; Wakabayashi, Toshiaki; Funahashi, Yasuhiro; Semba, Taro; Hata, Naoko; Yamamoto, Yuji; Ozawa, Yoichi; Tsukahara, Naoko

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan; et al.

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000050395	A1	20000831	WO 2000-JP1071	20000224
W: AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2000247949	A	20000912	JP 1999-49870	19990226
CA 2327253	A1	20000831	CA 2000-2327253	20000224
CA 2327253	C	20071016		
EP 1074542	A1	20010207	EP 2000-905321	20000224
EP 1074542	B1	20060503		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

HU 2001001434	A2	20010928	HU 2001-1434	20000224
HU 2001001434	A3	20011029		
RU 2208607	C2	20030720	RU 2000-129508	20000224
AU 766936	B2	20031023	AU 2000-26916	20000224
NZ 507464	A	20031031	NZ 2000-507464	20000224
CN 1132814	C	20031231	CN 2000-800229	20000224
AT 325094	T	20060615	AT 2000-905321	20000224
ES 2259997	T3	20061101	ES 2000-905321	20000224
JP 3866041	B2	20070110	JP 2000-600978	20000224
US 6469043	B1	20021022	US 2000-647215	20000928
MX 2000010243	A	20010410	MX 2000-10243	20001019
NO 2000005357	A	20001222	NO 2000-5357	20001024
NO 317299	B1	20041004		
US 20020128480	A1	20020912	US 2002-98420	20020318
US 6673787	B2	20040106		
US 20020128483	A1	20020912	US 2002-98421	20020318
US 6638964	B2	20031028		
JP 2006312652	A	20061116	JP 2006-226414	20060823
PRIORITY APPLN. INFO.:			JP 1999-49870	A 19990226
			JP 2000-600978	A3 20000224
			WO 2000-JP1071	W 20000224
			US 2000-647215	A3 20000928

OTHER SOURCE(S): MARPAT 133:193071
GI



AB The title compds. I [R1 represents hydrogen, etc.; R2 and R3 are the same or different and each represents hydrogen, etc.; R4 represents hydrogen or lower (C1-4) alkyl; and the ring A represents cyanophenyl, etc., provided that the following cases are excluded: the one where R1, R2 and R3 are all hydrogen atoms; the one where R2 and R3 are both hydrogen atoms; and the one where the ring A is an aminosulfonylphenyl group and R1 and R2 are both halogen atoms; and provided that when the ring A is a cyanophenyl, 2-amino-5-pyridyl or 2-halogeno-5-pyridyl group and R1 is a cyano group or a halogen atom, then at least one of R2 and R3 is not hydrogen] are prepared The title compound II in vitro showed IC50 of 10 µg/mL against mouse B16 melanoma cells.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 18 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:746753 HCAPLUS Full-text

DOCUMENT NUMBER: 132:88701

TITLE: Involvement of the histaminergic system in
leptin-induced suppression of food intakeAUTHOR(S): Morimoto, T.; Yamamoto, Y.; Mobarakeh, J. I.; Yanai,
K.; Watanabe, T.; Watanabe, T.; Yamatodani, A.CORPORATE SOURCE: Faculty of Medicine, School of Allied Health Sciences,
Department of Medical Physics, Osaka University,
Suita, Osaka, Japan

SOURCE: Physiology & Behavior (1999), 67(5), 679-683

CODEN: PHBHA4; ISSN: 0031-9384

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The ob gene product leptin is secreted from white adipose tissue, and may regulate food intake by acting on the hypothalamus in the central nervous system. But the mechanism of this effect is still unclear. The central histaminergic system has been suggested to participate in the control of various physiol. functions, particularly in feeding behavior, as it mediates anorectic signals like leptin. Thus, the authors hypothesized that the central histaminergic system is a target for leptin in its control of feeding. To prove this, the authors first examined the effect of i.p. administration of α -fluoromethylhistidine (FMH), a specific and irreversible inhibitor of histidine decarboxylase, on leptin-induced suppression of food intake in normal C57BL strain mice. Leptin treatment (1.3 mg/kg, i.p.) significantly reduced food intake by 60% of that of control at 6 h and by 84% at 24 h compared with control. When mice were injected with FMH (100 mg/kg, i.p.) before being given leptin, leptin-induced suppression of food intake was abolished and there was no significant difference compared with that of control. Addnl., the authors further examined the effects of leptin on food intake in mutant mice lacking histamine H1 receptors (H1R-KO mice). Leptin injection significantly reduced food intake by 56% of that of control at 6 h and by 79% at 24 h in wild-type mice (WT mice), but not in H1R-KO mice. This finding suggests that leptin affects the feeding behavior through activation of the central histaminergic system via histamine H1 receptors.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 19 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:420261 HCAPLUS Full-text

DOCUMENT NUMBER: 125:84454

ORIGINAL REFERENCE NO.: 125:15926h,15927a

TITLE: Human monoclonal rheumatoid factors augment arthritis
in mice by the activation of T cellsAUTHOR(S): Ezaki, I.; Okada, M.; Yoshikawa, Y.; Fujikawa, Y.;
Hashimoto, M.; Otsuka, M.; Nomura, T.; Yamamoto, K.;
Watanabe, T.; et al.CORPORATE SOURCE: Medical Institute Bioregulation, Kyushu University,
Oita, 874, JapanSOURCE: Clinical and Experimental Immunology (1996), 104(3),
474-482

CODEN: CEXIAL; ISSN: 0009-9104

PUBLISHER: Blackwell

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In order to investigate the in vivo role of rheumatoid factor (RF), the effects of the administration of human monoclonal (m) IgM-RF and IgG-RF on the development of arthritis in mice were examined. The administration of human mRFs into mice immunized with type II collagen (CII) markedly enhanced the clin. score and paw swelling. The severity of arthritic joint disease with a marked infiltration of lymphoid cells, proliferation of synovial membrane, pannus formation and destruction of articular cartilage was significantly enhanced in both groups receiving RF (RF-enhanced arthritis). Skin ulcers were also observed in some of these RF-enhanced arthritis mice, whereas no such signs were observed in CII-immunized mice without mRFs. Both IgM-RF and IgG-RF increased CII-specific IgG antibodies in circulation, and the severity of arthritis correlated with the production of high titers of anti-CII antibodies. In vivo treatment of RF-enhanced arthritis mice with an anti-CD4 MoAb or an anti-CD8 MoAb inhibited the induction and progression of arthritis in these mice. Administration of RF to severe combined immunodeficient (SCID) mice with arthritis developed by the transfer of spleen cells from CII-immunized mice, prolonged the arthritis and enhanced the severity. This murine model of RF-enhanced arthritis may provide a useful tool for analyzing the pathogenesis of rheumatoid arthritis in RF-pos. patients.

L23 ANSWER 20 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 1987:56343 HCAPLUS Full-text
 DOCUMENT NUMBER: 106:56343
 ORIGINAL REFERENCE NO.: 106:9223a,9226a
 TITLE: Heat capacities and adsorption energies of helium
 adsorbed on Y zeolites with various cations
 AUTHOR(S): Wada, N.; Yamamoto, Y.; Kato, H.; Ito, T.;
 Watanabe, T.
 CORPORATE SOURCE: Fac. Sci., Hokkaido Univ., Sapporo, 060, Japan
 SOURCE: Studies in Surface Science and Catalysis (1986),
 28(New Dev. Zeolite Sci. Technol.), 625-32
 CODEN: SSCTDM; ISSN: 0167-2991
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Influence of an elec. field of cation on He-adsorbed on Y zeolite and its motional state were studied by measuring the heat capacities and adsorption isotherms. The localization potential, W , that is van der Waals potential-enhanced by the elec. field to localize He near the cation, was estimated to be $W(\text{Ca}^{2+})/k > 170 \text{ K}$, $W(\text{Na}^{+})/k \text{ .apprx.} 28 \text{ K}$, and $W(\text{H}^{+})/k < 6 \text{ K}$. An isosteric heat of sorption obtained from the present adsorption isotherm has a very large temperature dependence in comparison with that assuming a classical oscillation or translation of the He adatom. This dependence may suggest discrete energy levels of the motional state due to a quantum effect confined into a small pore of diameter .apprx.10 Å.

L23 ANSWER 21 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1986:609267 HCAPLUS Full-text
 DOCUMENT NUMBER: 105:209267
 ORIGINAL REFERENCE NO.: 105:33755a,33758a
 TITLE: Absolute configuration at C-24 of 5 β -ranol, a
 principal bile alcohol of the bullfrog
 AUTHOR(S): Kihira, K.; Noma, Y.; Tsuda, K.; Watanabe, T.;
 Yamamoto, Y.; Une, M.; Hoshita, T.
 CORPORATE SOURCE: Sch. Med., Hiroshima Univ., Hiroshima, 734, Japan
 SOURCE: Journal of Lipid Research (1986), 27(4), 393-7
 CODEN: JLPRAW; ISSN: 0022-2275

DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The stereochem. of the hydroxyl group at C-24 in 5 β -ranol (I), a principal bile alc. of the bullfrog which is structurally related to a major human urinary bile alc., was described. Cholestenetetrols II were synthesized from cholic acid by the condensation of 24-aldehyde with vinylmagnesium bromide. The absolute configurations at C-24 of II were elucidated by means of the difference of the reactivity to Sharpless oxidation, a stereoselective epoxidn. Catalytic hydrogenation of II yielded tetrols III. Alternatively, III were prepared from norcholestanic acid by a Kolbe electrolytic coupling with acetic acid. The LiAlH₄ reduction of the norcholestanic acid provided I.

L23 ANSWER 22 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1984:163571 HCAPLUS Full-text

DOCUMENT NUMBER: 100:163571

ORIGINAL REFERENCE NO.: 100:24809a,24812a

TITLE: Experimental progress in plasma dynamics and generation of energetic particles in dense plasma focus

AUTHOR(S): Yokohama, M.; Kitagawa, Y.; Yamada, Y.; Okada, M.; Yamamoto, Y.; Yamanaka, C.; Hirano, K.; Kondoh, Y.; Shimoda, K.; et al.

CORPORATE SOURCE: Inst. Laser Eng., Osaka Univ., Suita, Japan

SOURCE: Plasma Physics and Controlled Nuclear Fusion Research (1983), Volume Date 1982, 9th(2), 415-24
 CODEN: PPCRDU; ISSN: 0589-1469

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The progress of recent expts. in dense plasma focus is described. Correlation between macroscopic behavior of focused plasma and n yield in 2 Mather-type devices, A and B, are presented. A Filippov-type device, C, was used to observe plasma dynamics including current sheet, imploding and reflected shock wave. In device A, nuclear activation is used for measuring d intensity,

energy spectrum and angular distribution. Cellulose nitrate particle-track detectors are used for high-energy p. Spatial and temporal locations of generation of high-energy ions are observed by ruby laser holog. interferometry. Ion pinhole cameras are used for determining the localization of high-energy ion generation. Energetic ions are produced and accelerated by a plasma diode. Ion temps. in focused plasma are estimated from measurement of the D-D/D-3He reaction ratios in a D2-3He mixture gas experiment. In the upstream and downstream directions with resp. to the discharge current, e and ion beams were observed in device B. The n were generated by a moving plasma diode mechanism. According to the measurement performed with a multiframing interferometer for device C, the highest collapse of the current sheet was attained at the collision between the collapsing current sheet and the related shock wave.

L23 ANSWER 23 OF 23 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1983:23857 HCAPLUS Full-text

DOCUMENT NUMBER: 98:23857

ORIGINAL REFERENCE NO.: 98:3667a,3670a

TITLE: Light ion beams generation in dense plasma focus

AUTHOR(S): Yokoyama, M.; Kitagawa, Y.; Yamada, Y.; Okada, M.; Yamamoto, Y.; Hori, T.; Yamanaka, C.

CORPORATE SOURCE: Inst. Laser Eng., Osaka Univ., Suita, 565, Japan

SOURCE: Res. Rep. - Nagoya Univ., Inst. Plasma Phys. (1982), IPPJ-611, Proc. Int. Top. Meet. ICF Res. Light - Ion Beam, 35-9

CODEN: NIPRAL; ISSN: 0469-4732

DOCUMENT TYPE: Report

LANGUAGE: English

AB High-energy d and p in a Mather-type plasma-focus device were measured by nuclear activation techniques. Radioactivity induced in graphite, Al, and Cu targets provided the d intensity, energy spectrum, and angular dependence. The high-energy p were measured by cellulose nitrate particle track detectors. The energy spectrum of d and p had 2 components and a mean d energy of 1.55 MeV under the low pressure mode and 1.44 MeV under the high pressure mode, resp. The angular distribution of the d beam was .ltorsim.30° under the low pressure mode. Under the high pressure mode, distribution showed multistructure, and 2 peaks were observed at .ltorsim.20 and .apprx.60°, resp., which may be due to the azimuthal rotation of the d around the axis.

=> d his nofile

FILE 'REGISTRY' ENTERED AT 07:19:26 ON 15 JUL 2009

L1 STR
 L3 107 SEA SSS FUL L1
 L4 STR
 L5 14 SEA SUB=L3 SSS FUL L4

FILE 'HCAPLUS' ENTERED AT 07:28:04 ON 15 JUL 2009

L6 26 SEA ABB=ON PLU=ON L5
 L7 20506 SEA ABB=ON PLU=ON ("SMALL-CELL LUNG CARCINOMA"/CV OR
 "CARCINOMA (L) PULMONARY SMALL-CELL"/CV OR "LUNG (L) SMALL-CELL
 CARCINOMA"/CV OR "LUNG, NEOPLASM (L) SMALL-CELL CARCINOMA"/CV
 OR "LUNG OAT CELL CARCINOMA"/CV OR "LUNG SMALL CELL CANCER"/CV)
 OR ("SMALL CELL CARCINOMA"/CV OR "SMALL CELL LUNG CANCER"/CV
 OR "SMALL LUNG CELL CARCINOMA"/CV OR "SMALL-CELL CARCINOMA
 (LUNG)"/CV OR "SMALL-CELL CARCINOMA (PULMONARY)"/CV) OR
 SMALL(L)CELL(L)LUNG(L)(CANCER? OR CARCINOMA)
 L8 4 SEA ABB=ON PLU=ON L6 AND L7
 D STAT QUE L8
 D IBIB ABS HITSTR L8 1-4
 L9 22 SEA ABB=ON PLU=ON L6 NOT L8
 L10 18 SEA ABB=ON PLU=ON L9 AND (?CANCER? OR ?CARCIN? OR ?TUMOR? OR
 ?MALIG? OR ?NEOPLAS?)
 L11 6 SEA ABB=ON PLU=ON L10 AND (LUNG OR PULMON?)
 D STAT QUE L11
 D IBIB ABS HITSTR L11 1-6
 L12 2293 SEA ABB=ON PLU=ON "YAMAMOTO Y"/AU OR YAMAMOTO Y ?/AU OR
 "YAMAMOTO YUJI"/AU
 L13 2815 SEA ABB=ON PLU=ON "WATANABE T"/AU OR WATANABE T ?/AU OR
 ("WATANABE TATSUO"/AU OR "WATANABE TATSURO"/AU)
 L14 949 SEA ABB=ON PLU=ON "OKADA M"/AU OR OKADA M ?/AU OR "OKADA
 MASAYUKI"/AU
 L15 41 SEA ABB=ON PLU=ON "TSURUOKA A"/AU OR "TSURUOKA AKIHIKO"/AU
 L16 19 SEA ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15)
 L17 8 SEA ABB=ON PLU=ON L13 AND (L14 OR L15)
 L18 1 SEA ABB=ON PLU=ON L14 AND L15

FILE 'REGISTRY' ENTERED AT 07:40:53 ON 15 JUL 2009

L19 93 SEA ABB=ON PLU=ON L3 NOT L5

FILE 'HCAPLUS' ENTERED AT 07:41:14 ON 15 JUL 2009

L20 16 SEA ABB=ON PLU=ON L19
 L22 14 SEA ABB=ON PLU=ON (L12 OR L13 OR L14 OR L15) AND (L6 OR L20)
 L23 23 SEA ABB=ON PLU=ON ((L16 OR L17 OR L18) OR L22) NOT (L8 OR
 L11)
 D STAT QUE L23
 D IBIB ABS HITSTR L23 1-23

=>